Company Overview of Prosensa Holding N.V.
Prosensa Holding B.V., a biotechnology company, engages in the discovery and development of ribonucleic acid-modulating therapeutics for the treatment of genetic disorders. The company’s products focus on the treatment of neuromuscular and neurodegenerative disorders, including duchenne muscular dystrophy (DMD), myotonic dystrophy, and huntington’s diseases. It develops drisapersen, which is in Phase III studies to restore dystrophin expression and enhancing muscle condition; PRO044 that is in Phase I/II studies to address a separate sub-population of DMD patients; and PRO045, PRO053, PRO052, and PRO055 to address other distinct sub-populations of DMD patients. The company also develops PRO1...
J.H. Oortweg 21
Leiden, 2333 CH
Founded in 1997
Key Executives for Prosensa Holding N.V.
Prosensa Holding N.V. does not have any Key Executives recorded.
Prosensa Holding N.V. Key Developments
Prosensa Holding NV to Elect Dr. Georges Gemayel as Supervisory Board Member
Dec 11 13
Prosensa Holding NV to elect Dr. Georges Gemayel as its new supervisory board member at Extraordinary Shareholders Meeting to be held on 23 January 2014. Currently, Dr. Gemayel is a member of the boards of NPS Pharmaceuticals, Orphazyme, Vascular Magnetics and EpiTherapeutics. Previously, Dr. Gemayel was the executive chairman of the board of FoldRx.
Prosensa Holding N.V. and Newcastle University Receive FP7 Research Grant from European Commission
Nov 25 13
Prosensa Holding N.V. and Newcastle University have announced the award of a second Framework Programme 7 (FP7) research grant from the European Commission. This new FP7 research grant totals approximately EUR 6 million to support the development of imaging biomarkers for Duchenne muscular dystrophy (DMD). The project - Developing imaging technologies for therapeutic interventions in rare diseases - will be known as BIOIMAGE-NMD and is expected to run three and a half years. The pan-European BIOIMAGE-NMD consortium includes leading expert centers in DMD already working together in another recently awarded FP7 project called SCOPE-DMD as well as additional partners with strong expertise and experience in bio-imaging. The SCOPE-DMD project, which was initiated earlier this year, was also awarded EUR 6 million as announced previously. This FP7 project aims to evaluate Prosensa's exon 45 skipping drug candidate, PRO045, in an innovatively designed clinical proof-of-concept study in boys with DMD. The academic partners in the BIOIMAGE-NMD project are Newcastle University as the coordinating partner, and University College London (UCL) in the United Kingdom; the Institute of Myology in France; the Leiden University Medical Centre in The Netherlands; Universita Cattolica del Sacro Cuore (UCSC) in Italy; and the Katholieke Universiteit Leuven (KULeuven) in Belgium. These academic centers are working alongside a number of industrial partners including Prosensa, SCITO, based in France, and Consultants for Research in Imaging and Spectroscopy (CRIS). BIOIMAGE-NMD will be conducting MRI scans in a number of exon skipping drug candidates, including PRO053, which is currently in Phase I/II clinical development. The compound induces exon 53 skipping in the dystrophin gene and could be suitable for up to 8% of all DMD patients.
Prosensa Holding N.V. Reports Unaudited Consolidated Financial Results for the Third Quarter and Nine Months Ended September 30, 2013
Nov 18 13
Prosensa Holding N.V. reported unaudited consolidated financial results for the third quarter and nine months ended September 30, 2013. For the quarter, the company reported revenue was EUR 2.4 million compared to EUR 2.3 million for the comparable period in 2012 due to decreased license income of EUR 0.6 million and increased collaboration revenue of EUR 0.7 million for the third quarter 2013. Loss per share attributable to the equity holders of the company was EUR 4.3 million compared to EUR 1.8 million for the same period a year ago. Total revenue was EUR 2,379,000 against EUR 2,301,000 a year ago. Operating loss was EUR 4,282,000 against EUR 1,937,000 a year ago. Basic and diluted loss per share was EUR 0.12 against EUR 0.07 a year ago.
For the nine months, the company reported loss per share attributable to the equity holders of the company of EUR 12.5 million against EUR 6.9 million for the comparable periods in 2012. Total revenue was EUR 6,763,000 against EUR 5,522,000 a year ago. Operating loss was EUR 12,334,000 against EUR 7,166,000 a year ago. Basic and diluted loss per share was EUR 0.40 against EUR 0.27 a year ago. Cash used in operating activities was EUR 17,289,000 against cash flow from operating activities of EUR 973,000 a year ago. Purchases of tangible fixed assets were EUR 426,000 against EUR 72,000 a year ago. Purchases of intangible assets were EUR 37,000 against EUR 139,000 a year ago.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|